Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

Area of Science:

• Immunology
• Endocrinology
• Diabetes Research

Background:

• Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic beta cells.
• Nondiabetic relatives of T1D patients are at high risk for developing the disease.
• Teplizumab is an immunotherapy agent that targets T cells.

Purpose of the Study:

• To analyze the long-term effects of a single 14-day course of teplizumab on metabolic function and immune cells in high-risk individuals for T1D.
• To evaluate the impact of teplizumab on time to T1D diagnosis and beta cell function.
• To investigate the relationship between changes in T cell subsets and clinical response to teplizumab.

Main Methods:

• Extended follow-up of a randomized controlled trial involving nondiabetic relatives at high risk for T1D.
• Analysis of metabolic parameters including glucose tolerance, C-peptide area under the curve (AUC), and insulin secretory rates.
• Characterization of T cell subsets and their function, specifically focusing on CD8+ T cells.

Main Results:

• Teplizumab treatment significantly delayed the median time to T1D diagnosis (59.6 months vs. 27.1 months for placebo).
• Fifty percent of teplizumab-treated participants remained diabetes-free compared to 22% of placebo-treated participants.
• Teplizumab improved beta cell function, evidenced by increased C-peptide AUC, and this improvement was associated with an increase in partially exhausted memory CD8+ T cells.

Conclusions:

• A single course of teplizumab has lasting effects in delaying T1D diagnosis and improving beta cell function in high-risk individuals.
• Changes in specific CD8+ T cell subsets, particularly partially exhausted effector cells, are associated with the clinical response to teplizumab.
• Teplizumab represents a promising immune therapy for delaying the onset of T1D and improving metabolic outcomes.